Recombinant Mycobacterium abscessus Elongation factor Tu (tuf)

What is Elongation Factor Tu (EF-Tu) in Mycobacterium abscessus and what is its significance?

Elongation Factor Tu (EF-Tu), encoded by the tuf gene, is a highly conserved protein essential for bacterial protein synthesis. In M. abscessus, as in other bacteria, EF-Tu plays a critical role in delivering aminoacyl-tRNAs to the ribosome during translation elongation. Beyond its canonical role in protein synthesis, EF-Tu has emerged as biologically significant because it is membrane-associated and potentially secreted in outer membrane vesicles (OMVs), as demonstrated in related bacterial species . This localization suggests it may have additional functions beyond translation, potentially in bacterial pathogenesis or host-pathogen interactions. M. abscessus is a rapidly growing non-tuberculous mycobacterium that causes a wide range of infections and is intrinsically resistant to many classes of antibiotics, making proteins like EF-Tu important targets for understanding its biology .

Is the tuf gene subject to horizontal gene transfer in M. abscessus, similar to other genes like rpoB?

While the search results do not explicitly mention horizontal gene transfer (HGT) of the tuf gene in M. abscessus, we know that HGT events are prevalent in this bacterium, particularly affecting genes like rpoB . The rpoB gene shows HGT in 4.1% of M. abscessus strains analyzed (74 out of 1,786 isolates), significantly higher than HGT rates for other genes like hsp65 (1.1%) . Given that EF-Tu is highly conserved and essential, researchers investigating potential tuf gene HGT should employ phylogenetic approaches similar to those used for rpoB analysis. This would involve:

• Extracting tuf gene sequences from whole-genome data of multiple M. abscessus isolates

• Performing phylogenetic inference to identify incongruence between tuf gene phylogeny and whole-genome phylogeny

• Analyzing sequence characteristics to identify potential recombination breakpoints

The methodology would be comparable to that used in the study of rpoB HGT, which identified subspecies-specific signatures and recombination events between M. abscessus subspecies .

How can the tuf gene be utilized for molecular typing and differentiation of M. abscessus subspecies?

The tuf gene could potentially serve as a molecular marker for typing M. abscessus strains, though its utility must be experimentally validated. Current molecular typing approaches for M. abscessus rely on genes like rpoB and hsp65, but these have shown limitations due to HGT events (as shown in Table 1, where rpoB-based identification shows only 95.58% agreement with core genome SNP-based identification) .

For researchers developing tuf-based typing methods, the recommended approach would include:

• Analyzing sequence conservation across subspecies (abscessus, massiliense, and bolletii)

• Identifying subspecies-specific polymorphisms in the tuf gene

• Developing PCR-based or sequence-based assays targeting these polymorphisms

• Validating the specificity against a diverse collection of clinical isolates

If the tuf gene proves stable against HGT, it might offer advantages over existing markers like rpoB, which shows discordance in 13.33% of M. massiliense strains .

What expression systems are optimal for producing recombinant M. abscessus EF-Tu?

For successful expression of recombinant M. abscessus EF-Tu, researchers should consider several expression systems, each with specific advantages:

• E. coli-based systems: The BL21(DE3) strain with pET vector systems offers high yield, though careful optimization is required to ensure proper folding of mycobacterial proteins. Recommended approaches include:

  • Using low induction temperatures (16-25°C)

  • Co-expression with chaperones (GroEL/GroES)

  • Testing multiple fusion tags (His, GST, MBP) for improved solubility

• Mycobacterial expression hosts: M. smegmatis-based expression systems may provide more appropriate post-translational modifications and folding environments for M. abscessus proteins, though with lower yields than E. coli.

The purification protocol should be designed based on the methodologies proven successful for similar bacterial elongation factors, including affinity chromatography followed by size exclusion chromatography to ensure high purity .

How can researchers verify the functional activity of purified recombinant M. abscessus EF-Tu?

Verifying functional activity of recombinant M. abscessus EF-Tu requires both structural integrity and biological function assessment:

• GTP binding and hydrolysis assays: As EF-Tu is a GTPase, measuring its ability to bind and hydrolyze GTP is essential. Recommended methods include:

  • Fluorescence-based GTP binding assays

  • Thin-layer chromatography to measure GTP hydrolysis

  • Malachite green phosphate detection for quantitative GTPase activity

• Aminoacyl-tRNA binding assays: Assess the protein's ability to form ternary complexes with GTP and aminoacyl-tRNAs using:

  • Gel filtration assays

  • Fluorescence anisotropy with labeled tRNAs

  • Surface plasmon resonance (SPR) for binding kinetics

• In vitro translation assays: Test EF-Tu functionality in reconstituted translation systems to confirm its ability to deliver aminoacyl-tRNAs to ribosomes.

These functional assays are critical to ensure that recombinant EF-Tu maintains native structure and activity before proceeding to experimental applications.

Does M. abscessus EF-Tu possess immunogenic properties similar to those observed in other bacterial species?

While the search results don't specifically address M. abscessus EF-Tu immunogenicity, evidence from Burkholderia research suggests bacterial EF-Tu is immunogenic during infection . In Burkholderia studies, EF-Tu was recognized by antibodies from infected mice, and immunization with recombinant EF-Tu induced both antibody and cell-mediated immune responses .

For researchers investigating M. abscessus EF-Tu immunogenicity, recommended methodologies include:

• Serological studies: Testing sera from M. abscessus-infected patients or animal models against recombinant M. abscessus EF-Tu to detect antibody responses.

• T-cell response assays: Evaluating whether EF-Tu stimulates T-cell proliferation and cytokine production using:

  • ELISpot assays to detect IFN-γ production

  • Flow cytometry for T-cell activation markers

  • Lymphocyte proliferation assays with purified recombinant EF-Tu

• Epitope mapping: Identifying immunodominant regions using:

  • Overlapping peptide libraries covering the entire EF-Tu sequence

  • Phage display libraries to identify antibody-binding epitopes

Given that Burkholderia EF-Tu is membrane-associated and secreted in OMVs, confirming similar localization in M. abscessus would support its potential role in host-pathogen interactions and immunogenicity .

How can recombinant M. abscessus EF-Tu be utilized in vaccine development research?

Building on findings from Burkholderia research where EF-Tu showed promise as a vaccine immunogen , researchers exploring M. abscessus EF-Tu as a vaccine candidate should consider:

• Immunization strategies: Testing various formulations, including:

  • Recombinant protein with appropriate adjuvants

  • DNA vaccines encoding EF-Tu

  • OMV-based vaccines that naturally contain EF-Tu

  • Mucosal immunization approaches, which showed efficacy with Burkholderia EF-Tu

• Protection assessment: Evaluating vaccine efficacy through:

  • Challenge studies in appropriate animal models

  • Measurement of bacterial loads in target organs

  • Survival analysis and disease progression monitoring

  • Immune correlates of protection (antibody titers, T-cell responses)

• Cross-protection analysis: Determining if immunization against M. abscessus EF-Tu provides protection against different subspecies or related mycobacterial species.

The Burkholderia research demonstrated that mucosal immunization with EF-Tu reduced lung bacterial loads in mice challenged with aerosolized bacteria, suggesting similar approaches might be valuable for respiratory M. abscessus infections .

What methods are most effective for studying interactions between M. abscessus EF-Tu and potential drug targets?

Investigating interactions between M. abscessus EF-Tu and potential drug compounds requires sophisticated structural and biochemical approaches:

• High-throughput screening methods:

  • GTPase activity assays to identify inhibitors of EF-Tu function

  • Thermal shift assays to detect compounds that bind and stabilize EF-Tu

  • Surface plasmon resonance (SPR) for real-time binding kinetics

• Structural biology techniques:

  • X-ray crystallography of EF-Tu with bound inhibitors

  • Cryo-EM studies of EF-Tu-ribosome complexes

  • NMR spectroscopy for mapping binding sites of small molecules

• Computational approaches:

  • Molecular docking simulations to predict binding modes

  • Molecular dynamics to understand conformational changes upon inhibitor binding

  • Virtual screening of compound libraries against EF-Tu structure

These methods can identify compounds that specifically target M. abscessus EF-Tu, potentially leading to novel antibiotics against this highly resistant pathogen .

How does the subcellular localization of EF-Tu in M. abscessus influence its potential roles beyond protein synthesis?

Based on findings from Burkholderia and other bacteria, EF-Tu may have non-canonical roles related to its membrane localization . To investigate this in M. abscessus, researchers should:

• Determine subcellular localization using:

  • Subcellular fractionation followed by immunoblotting

  • Immunoelectron microscopy to visualize EF-Tu distribution

  • Surface biotinylation assays to confirm surface exposure

  • Analysis of outer membrane vesicle (OMV) content

• Investigate potential moonlighting functions:

  • Adhesion assays to host cells and extracellular matrix components

  • Binding studies with host immune factors

  • Assessment of EF-Tu contribution to biofilm formation

  • Evaluation of potential role in antibiotic resistance mechanisms

The membrane association of EF-Tu in Burkholderia was demonstrated through careful fractionation studies that ruled out cytoplasmic contamination . Similar approaches in M. abscessus would clarify whether EF-Tu has similar dual localization and potential non-canonical functions.

How can CRISPR-Cas9 technologies be applied to study tuf gene function in M. abscessus?

Given that EF-Tu is likely essential for M. abscessus viability (as suggested by transposon mutagenesis studies of essential genes in M. abscessus ), CRISPR-Cas9 approaches must be carefully designed:

• Conditional knockdown systems:

  • CRISPRi (CRISPR interference) to reduce tuf expression rather than eliminate it

  • Inducible promoter systems to control tuf expression levels

  • Degron-tagged EF-Tu for controlled protein degradation

• Domain-specific modifications:

  • Precise editing of functional domains to study structure-function relationships

  • Introduction of point mutations that affect specific activities (GTP binding, tRNA interaction)

  • Creation of chimeric proteins to identify domain-specific functions

• Promoter reporter systems:

  • Integration of fluorescent reporters to monitor tuf expression under different conditions

  • CRISPR-based activation (CRISPRa) to study effects of tuf overexpression

These approaches would complement transposon mutagenesis studies that have already identified essential genes in M. abscessus, providing more nuanced understanding of EF-Tu function .

What are the most rigorous experimental designs for testing EF-Tu as a potential drug target in M. abscessus infections?

Developing EF-Tu-targeted therapeutics for M. abscessus requires systematic validation through several experimental stages:

• Target validation studies:

  • Conditional knockdown of tuf gene to confirm essentiality under various conditions

  • Complementation studies with wildtype and mutant EF-Tu variants

  • Analysis of growth phenotypes in different infection models

• Compound screening approaches:

  • Structure-based virtual screening against the GTP-binding pocket

  • Fragment-based drug discovery to identify novel binding scaffolds

  • Repurposing screens of approved antibiotics that might interact with EF-Tu

• Efficacy testing with increasing complexity:

  • In vitro activity against planktonic and biofilm cultures

  • Intracellular infection models using macrophages

  • Ex vivo lung tissue models

  • Animal models of acute and chronic M. abscessus infection

• Resistance development assessment:

  • Serial passage experiments to evaluate resistance emergence

  • Whole genome sequencing of resistant mutants

  • Structure-activity relationship studies to improve compound properties

Given the intrinsic antibiotic resistance of M. abscessus , targeting essential proteins like EF-Tu represents a promising avenue for new therapeutic development.